NEW YORK (TheStreet) -- TheStreet's Jim Cramer says MannKind (MNKD) is difficult to gauge because many people felt its inhaled insulin drug Afrezza would fail. As a result, 28% of the float was short and any positive news would send the stock upward.
Cramer says some believe the stock will go down again almost immediately. On the other hand, those who believe in the drug say this is the beginning of a major move for the stock because Mannkind has already spent so much money trying to get Afrezza developed.
Cramer remains "completely neutral" on this because "sometimes it's just better to admit that you don't know where something's going."